Antioxidants in the treatment of schizophrenia

Drugs of Today

Volumn 32, Issue 7, 1996, Pages 553-565

  Mahadik, Sahebarao P ^a   Gowda, Sridhar ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; NEUROLEPTIC AGENT;

DRUG SAFETY; GENE THERAPY; HUMAN; REVIEW; SCHIZOPHRENIA; STRESS;

EID: 0029729255     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. WHO. Schizophrenia: An International Follow-up Study. John Wiley and Sons: New York 1980.
2. Sartorious, N., Jablensky A., Korten, A. et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol Med 1986, 16: 909-28.
3. Torrey, F.E. Prevalence studies in schizophrenia. Br J Psychiatry 1987, 150: 598-608.
4. Jablensky A. Multicultural studies and the nature of schizophrenia: A review. J Royal Soc Med 1987, 80: 162-7.
5. Leff, J., Sartorious, N., Jablensky, A., Korten, A., Ernberg, G. The international pilot study of schizophrenia: Five-year follow-up findings. Psychol Med 1992, 22: 131-45.
6. van der Velde, C.D. Variability in schizophrenia. Arch Gen Psychiatry 1976, 33: 489-96.
7. Jeste, D.V., Kleinman, J.E., Potkin, S.G., Luchins, D.J., Weinberger, D.R. Ex uno multi: Subtyping the schizophrenic syndrome. Biol Psychiatry 1982, 17: 199-222.
8. Wyatt, R.J., Alexander, R.C., Eagan, M.F., Kirch, D.G. Schizophrenia, just the facts. What do we know, how well do we know it? Schizophr Res 1988, 1: 2-18.
9. Roberts, G.W., Crow, T.J. The neuropathology of schizophrenia - A progress report. Br Med Bull 1987, 43: 599-615.
10. Hyde, T.M., Casanova, M.F., Kleinman, J.E., Weinberger, D.R. Neuroanatomical and neurochemical pathology in schizophrenia. In: Reviews of Psychiatry, Vol. 10. Tasman, A., Goldfinger, S.M. (Eds.). Am Psychiat Press: Washington DC 1991, 7-23.
11. Bloom, F. Advancing neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993, 50: 224-7.
12. Fish, B., Marcus, J., Hans, S., Auerbach, J.G., Perdue, S. Infants at risk for schizophrenia: Sequelae of a genetic neurointegrative defect. Arch Gen Psychiatry 1992, 49: 221-35.
13. Zipursky, R.B., Lim, K.O., Sullivan, E.V. et al. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992, 49: 195-205.
14. Casanova, M.F., Stevens, J.R., Kleinman, J.E. The neuropathology of schizophrenia: Old and new findings. In: New Biological Vistas of Schizophrenia. Weinberger, D.R., Kleinman, J.E. (Eds.). Brunner/Mazel Publishers: New York 1993, 82-109.
15. Nasrallah, H.A. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr Clin 1993, 16: 269-80.
16. Selemon, L.D., Rajkowska, G., Goldman-Rakic, P.S. Abnormally high neuronal density in the schizophrenic cortex. Arch Gen Psychiatry 1995, 52: 805-18.
17. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1: 179-203.
18. Carlsson, M., Carlsson, A. Interaction between glutaminergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. TINS 1990, 13: 272-6.
19. Davis, K.L., Kahn, R.S., Ko, G., Davidson, M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991, 148: 1474-86.
20. Kahn, R.S., Davidson, M., Knott, P., Stern, R.G., Apter, S., Davis, K.L. Effects of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch Gen Psychiatry 1993, 50: 599-605.
21. Krystal, J.H., Seibyl, J.P., Price, L.H. et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993, 50: 624-35.
22. Carpenter, W.T. Jr. The treatment of negative symtpoms: Pharmacological and methodological issues. Br J Psychiatry 1996, 168 (Suppl. 29): 17-22.
23. Cadet, J.L., Lohr, J.b. Free radicals and the developmental pathophysiology of schizophrenic burnout. Integr Psychiatry 1987, 5: 40-8.
24. Mahadik, S.P., Mukherjee, S. Free radical pathology and antioxidant defense in schizophrenia: A review. Schizophr Res 1996, 19: 1-18.
25. Fridovich, I. Superoxide radical: An endogenous toxicant. Annu Rev Pharmacol 1983, 23: 239-57.
26. Halliwell, B., Gutteridge, J.M.C. (Eds.). Free Radicals in Biology and Medicine, 2. Clarendon Press: Oxford 1990.
27. Halliwell, B. Reactive oxygen species and the central nervous system. J Neurochem 1992, 59: 1609-23.
28. Packer, L. (Ed.). Oxygen Radicals in Biological Systems. Methods in Enzymology, Vol. 105. Academic Press: New York 1984.
29. Miguel, A., Quintanilha, A.T., Weber, H. (Eds.). CRC Handbook of Free Radicals and Antioxidants in Biomedicine, Vols. I-III. CRC Press: Boca Raton 1989.
30. Dawson, V.L., Dawson, T.M. Nitric oxide actions in neurochemistry. Neurochem Int 1996, 29: 97-110.
31. Beckman, J.S. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol 1991, 15: 53-9.
32. Lipton, S.A. Distinctive chemistries of NO-related species. Neurochem Int 1996, 29: 111-4.
33. Reddy, R., Mahadik, S.P., Mukherjee, S. Murthy, J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991, 30: 409-12.
34. Mukherjee, S., Mahadik, S.P., Correnti, E.E., Scheffer, R., Kelkar, H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19: 19-26.
35. Kramer, K., Voss, H.-P., Grimberger, J.A., Timmerman, H., Bast, A. The effects of ischemia and recirculation, hypoxia and recovery on antioxidant factors and β-adrenoreceptor density: Is the damage in erythrocytes a reflection of brain damage caused by complete cerebral ischemia and by hypoxia? Biochem Biophys Res Commun 1987, 149: 568-75.
36. Buckman, T.D., Kling, A.S., Eiduson, S., Sutphin, M.S., Steinberg, A. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol Psychiatry 1987, 22: 1349-56.
37. Buckman, T.D., Kling, A.S., Sutphin, M.S., Steinberg, A., Eiduson, S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: Relation to psychosocial variables. Psychiatry Res 1990, 31: 1-14.
38. Marchbanks, R.M., Mulcrone, J., Whatley, S.A. Aspects of oxidative metabolism in schizophrenia. Br J Psychiatry 1995, 167: 293-8.
39. Ames, B.N., Cathcart, R., Schwier, E., Hochstein, P. Uric acid, an antioxidant in humans against oxidant- and radical-caused aging and cancer. A hypothesis. Proc Natl Acad Sci USA 1981, 78: 6858-62.
40. Allebeck, P. Schizophrenia: A life-threatening disease. Schizophr Bull 1989, 15: 81-9.
41. Richardson Andrews, R.C. Unification of the findings in schizophrenia by reference to the effects of gestational zinc deficiency. Med Hypothesis 1990, 31: 141-53.
42. Brown, J.S. Jr. Role of selenium and other trace elements in the geography of schizophrenia. Schizophr Bull 1994, 20: 387-98.
43. Liday, L.A., Pippenger, C.E., Howard, A.A., Lieberman, J.A. Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: A pilot study. J Clin Psychopharmacol 1995, 15: 353-60.
44. Suboticanec, K., Folnegovic, V., Korbar, M., Mestrovic, B., Buzina, R. Vitamin C status in chronic schizophrenia. Biol Psychiatry 1990, 28: 959-66.
45. Capel, I.D. Factors affecting antioxidant defense potential. In: CRC Handbook of Free Radicals and Antioxidants in Biomedicine, Vol. II. Miguel, J., Quintanilha, A.T., Weber, H. (Eds.). CRC Press: Boca Raton 1989, 191-215.
46. Prilipko, L.L. Activation of lipid peroxidation under stress and in schizophrenia. In: New Research Strategies in Biological Psychiatry. Biological Psychiatry-New Perspectives: 3. Kemali, D., Morozov, P.V., Toffano, G. (Eds.). John Libbey: London 1984.
47. Pall, H.S., Williams, A.C., Blake, D.R., Lunec, J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987, ii: 596-7.
48. Lohr, J.B., Underbill, S., Moir, S., Jeste, D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1989, 28: 535-9.
49. Peet, M., Laugharne, J., Rangarajan, N., Renolds, G.P. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993, 8: 151-3.
50. McCreadie, R.G., MacDonald, E., Wiles, D., Campbell, G., Paterson, J.R. The Nithsdale schizophrenia surveys XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects. Br J Psychiatry 1995, 167: 1-8.
51. Evans, D.R., Puczkovski, P.Y., Brandsma, M.J., Mahadik, J.S., Mahadik, S.P. Elevated plasma lipid peroxides in schizophrenic patients without dementia. Biol Psychiatry 1996, 39: 588.
52. Mahadik, S.P., Mukherjee, S., Correnti, E.E., Scheffer, R. Elevated levels of lipid peroxidation products in plasma from drug-naive patient at the onset of psychosis. Schizophr Res 1995, 15: 66.
53. Simonian, N.A., Coyle, J.T. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996, 36: 82-106.
54. Cadet, J.L., Perumal, A.S. Chronic treatment with prolixin causes oxidative stress in rat brain. Biol Psychiatry 1990, 28: 738-40.
55. Murthy, J.N., Laev, H., Karpiak, S., Mahadik, S.P. Enzymes of oxyradical metabolism after haloperidol treatment of rat. Soc Neurosci 1989, 15: 139.
56. Heikkila, H.S., Cohen, G., Mannian, A.A. Reactivity of various phenothiazine derivatives with oxygen and oxygen radicals. Biochem Pharmacol 1975, 24: 363-8.
57. Cohen, G., Greenwald, R.A. (Eds.). Oxyradicals and Their Scavenger Systems, Vol. 1. Molecular Aspects. Proc Third Int Conf Superoxide and Superoxide Dismutase. Elsevier: Ellenville, NY 1983.
58. Shivakumar, B.R., Ravindranath, V. Oxidative stress and thiol modifications induced by chronic administration of halopridol. J Pharmacol Exp Ther 1993, 265: 1137-41.
59. Mahadik, S.P., Helio, L., Korenovsky, A., Karpiak, S.E. Haloperidol alters rat cholinergic system: Enzymatic and morphological analysis. Biol Psychiatry 1988, 24: 199-217.
60. Miller, R., Chouinard, G. Loss of striatal cholinergic neurons as a basis for tardive dyskinesia and L-dopa induced dyskinesia, neuroleptic induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993, 34: 713-38.
61. Vilner, B.J., de Costa, B.R., Bowen, W.D. Cytotoxic effects of sigma ligands: Sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 1995, 15: 117-34.
62. Jeding I., Evans, P.J., Akanmu, D. et al. Characterization of the potential antioxidant and prooxidant actions of some neuroleptic drugs. Biochem Pharmacol 1995, 49: 359-65.
63. 2 receptor supersensitivity. J Neurochem 1990, 54: 1137-41.
64. Subramanyam, B., Rollema, H., Wolf, T., Castagnoli, N.J.R. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rat. Biochem Biophys Res Commun 1990, 166: 238-44.
65. Behl, C., Lezoualch, F., Widmann, M., Ruprecht, R., Holsboer, F. Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res 1996, 717: 193-5.
66. Akbarian, S., Vinuela, A., Kim, J.J., Potkin, S.G., Bunney, W.E., Jones, E.G. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993, 50: 178-87.
67. Mahaidk, S.P., Mukherjee, S. Monosialoganglioside co-treatment prevents haloperidol treatment associated loss of cholinergic enzymes in rat brain. Biol Psychiatry 1995, 38: 246-54.
68. Fisher, A.B. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. Mol Pharmacol 1991, 40: 846-53.
69. Wyatt, R.J. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991, 17: 325-51.
70. Kirch, D.G., Keith, S.J., Mathews, S.M. Research on first-episode psychosis: Report on a National Institute of Mental Health Workshop. Schizophr Bull 1992, 18: 179-82.
71. Adler, L.A., Peselow, E., Rotrosen, J. et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150: 1405-7.
72. Meyers, D.G., Maloley, P.A., Weeks, D. Safety of antioxidant vitamins. Arch Intern Med 1996, 156: 925-35.
73. Burton, G.W., Ingold, K.U. Mechanisms of antioxidant action: Preventive and chain breaking antioxidants. In: CRC Handbook of Free Radicals and Antioxidants in Biomedicine, Vol. II. Miguel, J., Quintanilha, A.T., Weber, H. (Eds.). CRC Press: Boca Raton 1989, 29-43.
74. Frei, B., England, L., Ames, B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 1989, 86: 6377-81.
75. Braughler, J.M., Pregenzer, J.F., Chase, R.L. et al. Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 1987, 262: 10438-40.
76. Rice-Evans, C.A., Diplock, A.T. Current status of antioxidant therapy. Free Rad Biol Med 1993, 15: 77-96.
77. May, J.M., Qu, Z.-C., Morrow, J.D. Interaction of ascorbate and α-tocopherol in resealed erythrocyte ghosts. J Biol Chem 1996, 271: 10577-82.
78. Jackson, G.R., Apfell, L., Werrbacch-Perez, K., Perez-Poto, J.R. Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance. J Neurosci Res 1990, 25: 360-9.
79. Nistico, G., Ciriolo, M.R., Fiskin, K., Iannone, M., Martino, A., Rotillo, G. NGF restores decreases in catalase activity and increases superoxide dismutase and glutathione peroxidase activity in the brain of aged rats. Free Radical Biol Med 1992, 12: 177-81.
80. Spina, M.B., Squinto, S.P., Miller, J., Lindsay, R.M., Hyman, C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system. J Neurochem 1992, 59: 99-106.
81. 2 toxicity. J Appl Physiol 1984, 57: 1674.
82. Chan, P.H., Longar, S., Fishman, R.A. Protective effects of liposome-trapped superoxide dismutase on post-traumatic brain edema. Ann Neurol 1987, 21: 282-6.
83. Chan, P.H., Chu, L., Chen, S.F., Carlson, E.J., Epstein, C.J. Reduced neurotoxicity in transgenic mice overexpressing human copper-zinc-superoxide dismutase. Stroke 1990, 21 (Suppl. III): 80-2.
84. Gurney, M.E., Chiu, A.Y., Dal Canto, M.C., Trojanowski, J.Q., Lee, V.M.-Y. Mutations of human Cu,Zn superoxide dismutase expressed in transgenic mice cause motor neuron disease. In: Neurodegenerative Diseases: Molecular and Cellular Mechanisms and Therapeutic Advances. George Washington Univ Med Center, Dept Biochem Mol Biol Annu Spring Symp. G. Fiskum, G. (Ed.). Plenum Press: New York 1996, 113-22.
85. Sohal, R.S., Ku, H.-H., Agarwal, S., Forster, M.J., Lal, H. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging and in response to food restriction in the mouse. Mech Aging Dev 1994, 74: 121-33.
86. Ku, H.-H., Brunk, U.T,. Sohal, R.S. Relationship between mitochondrial superoxide and hydrogen peroxide production and longevity of mammalian species. Free Radic Biol Med 1993, 15: 621-7.
87. Mosoro, E.J. A critical review: Nutrition and ageing - A current assessment. J Nutr 1984, 115: 842-8.
88. Allen, R.G. Oxygen-reactive species and antioxidant responses during development: The metabolic paradox of cellular differentiation. Proc Soc Exp Biol Med 1991, 196: 117-29.
89. Allen, R.G, Balin, A.K. Oxidative influence on development and differentiation: An overview of a free radical theory of development. Free Radic Biol Med 1989, 6: 631-61.
90. Simopoulos, A.P. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991, 54: 438-63.
91. Wainwright, P.E. Do essential fatty acids play a role in brain and behavioral development? Neurosci Biobehav Rev 1992, 16: 193-205.
92. Forster, M.J., Dubey, A., Dawson, K.M., Stutts, W.A., Lal, H., Sohal, R.S. Age-related losses of cognitive and motor skills in mice are associated with oxidative protein damage in the brain. Proc Natl Acad Sci USA 1996, 93: 4765-9.
93. Yamamoto, N., Saitoh, M., Moriuchi, A., Nomura, M., Okuyama, H. Effect of dietary α-linolenate/linoleate balance on brain lipid compositions and learning ability of rats. J Lipid Res 1987, 28: 144-51.
94. Neuringer, M., Connor, W.E., Lin, D.S., Barstad, L., Luck, S. Biochemical and functional effect of prenatal and postnatal ω3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci USA 1986, 83: 4021-5.
95. Coon, H., Byerley, W., Holik, J. et al. Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am J Hum Genet 1993, 52: 327-34.
96. 2 receptor gene in alcoholism or schizophrenia. JAMA 1994, 271: 204-8.
97. Agranoff, B. Lipids. In: Basic Neurochemistry, 4th Ed. Siegel, G.J., Albers, R.W., Agranoff, B.W., Katzman, R. (Eds.). Little, Brown and Company: Boston 1989, 91-107.
98. Rana, R.S., Hokin, L.E. Role of phosphoinositols in transmembrane signaling. Physiol Rev 1990, 70: 115-64.
99. 2 and arachidonic acid release in signal transduction. Biochem Soc Trans 1990, 18: 503-7.
100. 2 receptor synergism. Nature 1991, 353: 164-7.
101. 2 dopamine receptors is reduced in scizophrenia and Huntington diseased brains. Proc Natl Acad Sci USA 1989, 86: 10156-60.
102. 2: Possible role of oxygen radicals. J Neurochem 1988, 50: 565-71.
103. Rafalowska, U., Liu, G.-J., Floyd, R.A. Peroxidation induced changes in synaptosomal transport of dopamine and γ-aminobutyric acid. Free Radic Biol Med 1989, 6: 485-92.
104. Essali, M.A., Das, R., de Belleroche, J., Hirsch, S.R. The platelet polyphosphoinositite system in schizophrenia: The effects of neuroleptic treatment. Biol Psychiatry 1990, 28: 478-87.
105. Kaiya, H., Nishida, A., Imai, A., Nakashima, S., Nozawa, Y. Accumulation of diacylglycerol in platelet phosphoinositides turnover in schizophrenia: A biological marker of good prognosis? Biol Psychiatry 1989, 26: 669-76.
106. Hudson, C.J., Young, L.T., Li, P.P., Warsh, J.J. CNS signal transduction in the pathophysiology and pharmacology of affective disorders and schizophrenia. Synapse 1993, 13: 278-93.
107. Yao, J.K., Yasaei, P., van Kammen, D.P. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandin Leukot Essent Fat Acids 1993, 46: 39-46.
108. Mahadik, S.P., Mukherjee, S., Correnti, E.E., Scheffer, R. Altered signal transduction in fibroblasts from first-episode schizophrenic patients. Biol Psychiatry 1996, 39: 519.
109. Trotti, D., Danbolt, N.C., Rizzini, B.L. et al. Glutamate transporters: Molecular mechanisms of functional alteration and the role in the development of excitotoxic neuronal injury. In: Neurodegenerative Diseases: Molecular and Cellular Mechanisms and Therapeutic Advances. George Washington Univ Med Center, Dept Biochem Mol Biol Annu Spring Symp. Fiskum, G. (Ed.). Plenum Press: New York 1996, 33-6.
110. Olney, J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52: 998-1007.
111. Rotrosen, J., Wolkin, A. Phospholipid and prostaglandin hypotheses of schizophrenia. In: Psychopharmacology: The Third Generation of Progress. Meltzer, H.Y. (Ed.). Raven Press: New York 1987, 759-64.
112. Pettegrew, J.W., Keshavan, M.S. et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch Gen Psychiatry 1991, 48: 563-8.
113. Horrobin, D.F., Glen, A.I.M., Vaddadi, K.S. The membrane hypothesis of schizophrenia. Schizophr Res 1994, 13: 195-208.
114. Mahadik, S.P., Mukherjee, S., Correnti, E. et al. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res 1994, 13: 239-47.
115. Glen, A.I.M., Glen, E.M.T., Horrobin, D.F. et al. A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two diseases. Schizophr Res 1994, 12: 53-61.
116. Peet, M., Horrobin, D.F., Reynolds, G.P. Arachidonic acid: A common link in the biology of schizophrenia. Arch Gen Psychiatry 1994, 51: 665-6.
117. Yao, J.K., van Kammen, D.P., Welker, J.A., Gurklis, J. Fled blood cell membrane dynamics in schizophrenia: Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 1994, 13: 227-32.
118. Mahadik, S.P., Mukherjee, S,. Correnti, E.E., Scheffer, R. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: Comparison with bipolar and normal controls. Psychiatr Res 1996, 63: 133-42.
119. Horrobin, D.F., Manku, M.S., Hillman, S., Glen, I.A.M. Fatty acid levels in brains of schizophrenics and normal controls. Biol Psychiatry 1991, 30: 795-805.